These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 19493247)
1. Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes. Gottschalk M; Danne T; Fuerst-Recktenwald S Pediatr Diabetes; 2009 Jun; 10(4):240-7. PubMed ID: 19493247 [No Abstract] [Full Text] [Related]
2. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance. Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404 [No Abstract] [Full Text] [Related]
3. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer. Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427 [No Abstract] [Full Text] [Related]
4. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007 [TBL] [Abstract][Full Text] [Related]
6. When--and how--to use an oral agent. Shuman CR Med Times; 1980 May; 108(5):77-81, 85-6. PubMed ID: 7374409 [No Abstract] [Full Text] [Related]
7. Pareto's law and sulfonylureas. Peiris AN; Micklewright M; Gangadharan V South Med J; 2007 Nov; 100(11):1072-3. PubMed ID: 17984734 [No Abstract] [Full Text] [Related]
8. Oral hypoglycemic agents and heart. Manoria P; Manoria P Indian Heart J; 2007; 59(3):266-72. PubMed ID: 19124937 [No Abstract] [Full Text] [Related]
14. Oral therapeutic system delivering a water insoluble drug: N-(4-[2-(3-methylpyrazole-1-carbonamide)ethyl]-benzenesulfonyl)N - cyclohexylurea (SPC-5002). Janicki S; Jedras Z; Sawicki W Acta Pharm Hung; 1988 Jul; 58(4):145-51. PubMed ID: 3223284 [No Abstract] [Full Text] [Related]
15. [Metformin in serum. Results of a study as basis for preliminary therapeutic recommendations]. Frid A; Sterner G; Löndahl M; Vinge E; Cato A; Andersson A Lakartidningen; 2009 Feb 11-17; 106(7):428-9. PubMed ID: 19350768 [No Abstract] [Full Text] [Related]
16. [Oral blood glucose-lowering medication as a monotherapy in gestational diabetes: a hotly debated topic]. de Valk HW Ned Tijdschr Geneeskd; 2009; 153():A330. PubMed ID: 19785815 [TBL] [Abstract][Full Text] [Related]
17. Clinical management of type 2 diabetes in indigenous youth. Sellers EA; Moore K; Dean HJ Pediatr Clin North Am; 2009 Dec; 56(6):1441-59. PubMed ID: 19962030 [TBL] [Abstract][Full Text] [Related]
19. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040 [No Abstract] [Full Text] [Related]
20. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]